Peptide Injections AI
All Briefings

May 29, 2026

Friday, May 29, 2026

Today: 8 trending tweets, 8 new studies.

New Research

Trending on X

Hunter Williams@HunterEsoteric

Everyone says peptides cause cancer. I pulled the studies. Here's what they actually show. 06:25 BPC-157 08:40 DSIP 09:54 Epitalon 12:15 GHK-Cu 14:45 KPV 16:03 LL-37 18:41 MOTS-c 20:00 Retatrutide 21:19 Semaglutide 22:24 SS-31 24:13 Thymosin Alpha-1 25:47 Tirzepatide https://t.co/2RBkMubEQP

708 likes81 retweets
Smart Science@SmartScience

Popular obesity medications significantly lower overall cancer risk, study finds. The breakthrough class of obesity medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP receptor agonists like tirzepatide, continue to make waves in modern medicine. https://t.co/Bul3Icqy4F

32 likes9 retweets
Allison@melodyisdestiny

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

0 likes7 retweets
BarakaFlockaFlame@CookNTweet

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

0 likes7 retweets
Get Your Seat At the Table@ActsofFaithblog

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

0 likes7 retweets
Beachfield Vasque@postingpirate

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

0 likes7 retweets
ninguém se importa@vivinhapimentah

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

0 likes7 retweets
Disclosed Labs@DisclosedLabs

What 2026 research-chem buyers actually order — top 10 by share of all in-scope COAs in our corpus over the last 60 days: Retatrutide — 10.4% Tirzepatide — 8.5% BPC-157 — 7.8% GHK-Cu — 4.8% Tesamorelin — 4.4% MOTS-C — 4.1% Ipamorelin — 3.8% NAD+ — 3.2% Semaglutide — 3.1% TB-500

8 likes0 retweets

Provider Spotlight

Ivim Health

Telehealth platform offering peptide therapy and GLP-1 weight management with clinical oversight.